arrow
M

Mi Kwon

Hospital General Universitario Gregorio Marañon
H指数:32
被引数:3,827

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma ST2 and Angiopoietin-2, but Not Hyaluronan, Retain Discriminatory Performance for Sinusoidal Obstruction Syndrome after Allogeneic HSCT with High-Dose Post-Transplant Cyclophosphamide

血浆ST2和血管生成素-2,而非透明质酸,在异基因HSCT联合高剂量移植后环磷酰胺治疗后仍保持对窦状阻塞性综合征的鉴别诊断性能

2026-10-230
PRE
Bridging therapy in pediatric and AYA patients under 25 years with relapsed/refractory B-ALL undergoing anti-CD19 CAR-T therapy: a multicenter retrospective study by the Spanish group GETH-TC

25岁以下复发/难治性B-ALL儿科及青少年成年过渡期患者接受抗CD19 CAR-T治疗时的桥接治疗:西班牙GETH-TC多中心回顾性研究

2026-10-120
PRE
Timing of Allogeneic Hematopoietic Cell Transplantation After Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-ALL

异基因造血细胞移植在奥佐米星之后的时机影响窦状阻塞综合征和复发/难治性B-ALL患者的生存

2026-08-150
PRE
Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
2026-07-200
PRE
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWP

体细胞共发生突变在急性髓系白血病移植后结局中的频率和影响:一项代表EBMT ALWP的多中心登记研究

2025-12-050
PRE
Predictive biomarkers validation of CD3+ cell apheresis yield in CAR-T manufacturing for diffuse large B-cell lymphoma: a machine learning approach

弥漫性大B细胞淋巴瘤CAR-T制造中CD3+细胞去除术产量的预测生物标志物验证:一种机器学习方法

2025-11-280
OAAI
Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMT

供者选择在PTCy半相合移植治疗急性淋巴细胞白血病中的应用:一项来自EBMT ALWP的研究

2025-11-250
PRE
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy

大B细胞淋巴瘤患者接受CAR T细胞治疗时的患者选择与治疗结果随时间的变化

2025-09-300
PRE
Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in the public Chilean national health system: A single center study

haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in the public Chilean national health system:一项单中心研究

2025-09-010
OAAI
Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

添加抗胸腺细胞球蛋白对异基因移植后环磷酰胺的影响(与外周血相比):与单独使用异基因移植后环磷酰胺相比的影响:代表欧洲血液与骨髓移植学会细胞治疗与免疫生物学工作组进行的一项回顾性研究

2025-08-070
OAAI
ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling

CD19 car-t治疗中的ICANS风险模型: 来自血清和CSF细胞因子分析的见解

2025-07-240
OAAI
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy

结外受累的大B细胞淋巴瘤的位点特异性分析揭示了嵌合抗原受体T细胞疗法的独特疗效

LEUKEMIA
IF13.4
2025-04-010
PRE
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

嵌合抗原受体T细胞疗法在T细胞/组织细胞丰富的大B细胞淋巴瘤中的疗效及疾病进展后的后续治疗策略:一项GELTAMO/GETH研究

2025-02-040
OAAI
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
LEUKEMIA
IF13.4
2024-11-190
PRE
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
2024-11-070
OAAI
Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

通过肠道微生物组和丁酸盐增强非霍奇金淋巴瘤的CAR-T细胞疗法

BLOOD
IF23.1
2024-11-050
PRE
Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia

异基因移植联合氯法拉滨和基于移植后环磷酰胺的预处理在极高风险急性髓系白血病患者中的疗效

BLOOD
IF23.1
2024-11-050
PRE
BONE Marrow Chimerism and Measurable Residual Disease Analysis Interplay: Impact on Prognosis of ACUTE Myeloid Leukemia Undergoing STEM Celltransplatation

骨髓嵌合与可测量残留病灶分析相互作用:对接受干细胞移植的急性髓系白血病预后的影响

BLOOD
IF23.1
2024-11-050
PRE
Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

体细胞突变单独或联合对急性髓系白血病移植后结局的频率和影响:一项由EBMT急性白血病工作组发起的大规模研究

BLOOD
IF23.1
2024-11-050
PRE